ラクトフェリン　2013

出版社： 日本医学館
著者：
発行日： 2013-10-30
分野： 基礎・関連科学  >  基礎医学関連科学一般
ISBN： 9784890447794
電子書籍版： 2013-10-30 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

商品紹介

日本ラクトフェリン学会第5回学術集会（2012年10月27日、於　昭和大学）での発表内容をまとめたもの。

目次

  • ラクトフェリン　2013

    ―目次―

    特別講演
    　Lactoferrin and lactoferrin receptors during infancy

    シンポジウム1　ラクトフェリンと女性の健康（全年齢）
    　1．皮膚へのラクトフェリンの作用に及ぼす
    　　　ソホロリピッドの影響
    　2．ラクトフェリンによる早産予防の可能性

    シンポジウム2　ラクトフェリンと女性の健康（更年期）
    　1．ラクトフェリンによる骨吸収抑制作用と
    　　　その分子生物学的メカニズム
    　2．骨芽細胞様細胞を用いた石灰化促進作用に対する
    　　　ラクトフェリンの効果
    　3．ラット内側性骨欠損に対するラクトフェリンの影響

    一般演題およびポスターセッション
    　1．HTLV-1のTax発現リンパ腫細胞のウシラクトフェリンによる
    　　　腫瘍増殖抑制効果
    　2．ラット瞬き減少型ドライアイモデルにおける
    　　　ラクトフェリンの涙液分泌能に与える影響
    　3．ラクトフェリンを配合した化粧品の使用による皮膚の評価
    　4．炎症性腸疾患動物モデルにおけるラクトフェリンの効果
    　5．ラクトフェリンはシスプラチン誘発腎不全における
    　　　白金の蓄積を抑制する
    　ほか

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[シンポジウム1]

P.10 掲載の参考文献
1) Hirata Y, Ryu M, Igarashi K, Nagatsuka A, Furuta T et al.: Natural synergism of acid and lactone type mixed sophorolipids in interfacial activities and cytotoxicities. J Oleo Sci 58: 565-572, 2009.
PubMed
2) Ishibashi T: Three-dimensional skin cultured model testskin, fabrication and applications. Soshiki Baiyo Kogaku 25: 121-124, 1999.
 
3) Zhou QH, Klekner V, Kosaric N: Production of sophorose lipids by Trulopsis bombicola from safflower oil and glucose. J Am Oil Chem Soc 69: 89-91, 1992.
 
4) Watanabe T, Hasegawa T, Takahashi H, Ishibashi T K S: Effect of penetration enhancers on the permeation of drugs across a three-dimensional cultured human skin model: comparison with the effects using excised hairless rat skin. Altern Animal Test Experiment 8: 15-22, 2001.
 
5) Ishii N, Kobayashi T, Matsumiya K, Ryu M, Hirata Y et al.: Transdermal administration of lactoferrin with sophorolipid. Biochem Cell Biol 90: 504-512, 2012.
PubMed
6) Braun E, Wagner A, Furnschlief E, Katinger H, Vorauer-Uhl K: Experimental design for in vitro skin penetration study of liposomal superoxide dismutase. J Pharm Biomed Anal 40: 1187-1197, 2006.
PubMed
7) Suzuki YA, Lonnerdal B: Lactoferrin: structure, functions, and applications. Funct Food Rev 2: 69-79, 2010.
 
8) DuPlessis ER, Rohlfs RJ, Hille R, Thorpe C: Electron-transferring flavoprotein from pig and the methylotrophic bacterium W3A1 contains AMP as well as FAD. Biochem Mol Biol Int 32: 195-199, 1994.
PubMed
9) Anderson BF, Baker HM, Dodson EJ, Norris GE, Rumball SV et al.: Structure of human lactoferrin at 3. 2-A resolution. Proc Natl Acad Sci USA 84: 1769-1773, 1987.
PubMed
10) Sharma S, Jasti J, Kumar J, Mohanty AK, Singh TP: Crystal structure of a proteolytically generated functional monoferric C-lobe of bovine lactoferrin at 1. 9A resolution. J Mol Biol 331: 485-496, 2003.
 
11) Almond A: Hyaluronan. Cell Mol Life Sci 64: 1591-1596, 2007.
PubMed
12) Saito S, Takayama Y, Mizumachi K, Suzuki C: Lactoferrin promotes hyaluronan synthesis in human dermal fibroblasts. Biotechnol Lett 33: 33-39, 2011.
PubMed
13) Antonicelli F, Bellon G, Lorimier S, Homebeck W: Role of the elastin receptor complex(S-Gal/Cath-A/Neu-1)in skin repair and regeneration. WoundRepair Regen 17: 631-638, 2009.
 
14) Saunders J, Davis H, Coetzee L, Botha S, Kruger A et al.: A novel skin penetration enhancer: evaluation by membrane diffusion and confocal microscopy. J Pharm Pharm Sci 2: 99-107, 1999.
 
15) Hirata Y, Ryu M, Oda Y, Igarashi K, Nagatsuka A et al.: Novel characteristics of sophorolipids, yeast glycolipid biosurfactants, as biodegradable lowfoaming surfactants. J Biosci Bioeng 108: 142-146, 2009.
PubMed
P.18 掲載の参考文献
1) Otsuki K, Yoda A, Hirose K, Shimizu Y, Saito H et al.: Salivary lactoferrin in neonates with chorioamnionitis. Showa Univ J Med Sci 9(1): 39-44, 1997.
 
2) Otsuki K, Yoda A, Toma Y, Shimizu Y, Saito H et al.: Lactoferrin and interleukin-6 interaction in amniotic infection. Adv Exp Med Biola 443: 267-271, 1998.
 
3) Sawada M, Otsuki K, Yakuwa K, Mitsukawa K, Nagatsuka M et al.: Cervical inflammatory cytokines and other markers in cervical mucus of pregnant women with lower genital tract infections. Int J Gynecol Obstet: 117-121, 2006.
 
4) 大槻克文, 斎藤 裕, 矢内原巧: サンドイッチ ELISA法を用いた新生児唾液中ラクトフェリン濃度の測定. 日本産科婦人科栄養・代謝研究会誌 2(1): 67, 1996.
 
5) 依田 暁, 大槻克文, 藤間芳郎, 清水幸子, 斎藤 裕・他: 絨毛膜羊膜炎における羊水中Lactoferrin 測定の臨床的意義. 日本産科婦人科栄養・代謝研究会誌 3(1): 57-58, 1997.
 
6) Otsuki K, Yoda A, Mitsuhashi Y, Toma Y, Shimizu Y et al.: Amniotic fluid lactoferrin in intrauterine infection. Placenta Mar-Apr 20(2-3): 175-179, 1999.
 
7) Otsuki K, Yoda Y, Mitsuhashi Y, Shimizu Y, Saito H et al.: Isolation and detection of human lactoferrin binding protein in human amniotic membrane. Lactoferrin: Structure. Function and Applications: 343-346, 2000.
 
8) 齋藤 裕, 大槻克文, 依田 暁, 矢内原巧: 子宮内感染と早産-子宮内感染におけるラクトフェリンの感染防御機構について. 周産期学シンポジウム 16号: 111-114, 1998.
 
9) 依田 暁, 大槻克文, 三橋裕一, 清水幸子, 齋藤 裕・他: 絨毛膜羊膜炎をきたした早産症例における羊水中ラクトフェリンとIL-6の動態. 日本新生児学会雑誌 34巻3号 506-510, 1998.
 
10) Saito H, Otsuki K, Mitsuhashi Y, Yoda Y, Yanaihara Aet al.: Role of lactoferrin in the prevention of preterm delivery. Lactoferrin: Structure, Function and Applications: 347-352, 2000.
 
11) Mitsuhashi Y, Otsuki K, Yoda Y, Shimizu Y, Saito H et al.: Effect of lactoferrin on lipopolysaccharide(LPS)induced preterm delivery in mice. Acta Obstet Gynecol Scand 79: 355-358, 2000.
 
12) Sherman MP, Otsuki K, Lonnerdal BL: Preventing Escherichia coli growth on cervical epithelium. Pediatr Res 49: 232A, 2001.
 
13) Otsuki K, Lonnerdal BL, Sherman MP: Lactoferrin: Bacterial opsonin for macrophages? Biochemistry and Cell Biology 80: 158, 2002.
 
14) Otsuki K, Lonnerdal BL, Sherman MP: Bacterial growth on human cervical epithelia: A new assay for testing killing by lactoferrin. Biochemistry and Cell Biology 80: 165, 2002.
 
15) Sasaki Y, Otsuki K, Hasegawa A, Sawada M, Chiba H, Negishi M, Nagatsuka M, Okai T: Preventive effect of recombinant human Lactoferrin on lipopolysaccharide-induced preterm delivery in mice. Acta Obstet Gynecol Scand 83: 1035-1038, 2004.
PubMed
16) Otsuki K, Sasaki Y, Hasegawa A, Sawada M, Mitsukawa K et al.: Lactoferrin concentrations in cervical mucus of pregnant women with and without infection. Am J Obstet Gynecol 191: S75, 2004.
 
17) Hasegawa A, Otsuki K, Sasaki Y, Sawada M, Mitsukawa K et al.: Preventive effect of recombinant human lactoferrin in a rabbit preterm delivery model. Am J Obstet Gynecol 192: 1038-1043, 2005.
 
18) Otsuki K, Hasegawa A, Sasaki Y, Sawada M, Yakuwa Ket al.: Potential of lactoferrin in the prevention of preterm delivery. Taiwanese J Obstet Gynecol 44: 123-127, 2005.
 
19) Otsuki K, Yakuwa K, Sawada M, Hasegawa A, Sasaki Yet al.: Recombinant human lactoferrin has a preventive effects on lipopolysaccharide-induced preterm delivery and production of inflammatory cytokines. J Perinat Med 33: 320-323, 2005.
 
20) 大槻克文, 長谷川明俊, 澤田真紀, 満川香織, 千葉 博・他: ラクトフェリンによる体内での炎症性サイトカイン産生抑制を解した早産予防の試み. Milk Science 53(4): 304-305, 2004.
 
21) 長谷川明俊, 大槻克文, 佐々木康, 澤田真紀, 満川香 織・他: ラビット早産モデルにおけるlactoferrinの早産防止効果. Milk Science 53(4): 306-308, 2004.
 
22) 長谷川明俊, 大槻克文, 佐々木康, 澤田真紀, 千葉 博・他: マウス早産モデルにおけるRecombinant human lactoferrinの早産防止効果. 日本周産期・新生児医学会雑誌 40(1): 35-39, 2004.
Medical*Online
23) 大槻克文: 超早産の病態, 予後及び予防への展望 Lactoferrinによる超早産予防の可能性. 日本周産期・新生児医学会雑誌 40(4): 759-762, 2004.
 
24) Romero R Yoon BH, Mazor M et al. The diagnostic and prognostic value of amniotic fluid white blood cell count, glucose, interleukin-6, and gram stain in patients with preterm labor and intact membranes. Am. J. Obstet Gynecol 169: 805-816, 1993.
PubMed
25) Yoon BH, Park CW, Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. Br J Obstet Gynecol 110 Suppl 20: 124-127, 2003.
 
26) Dudley DJ. Pre-term labor: an intra-uterine inflammatory response syndrome? J Reprod Immunol 36: 93-109, 1997.
PubMed
27) Sahlin, L. et al.: Impaired leukocyte influx in cervix of postterm women not responding to prostaglandin priming. Reprod Biol Endocrinol 6: 36, 2008.
 
28) Kaga N, Katsuki Y, Obata M et al.: Repeated administration of low-dose lipopolysaccharide induces preterm delivery in mice. A model for human preterm parturition and for assessment of the therapeutic ability of drugs against preterm delivery. Am J Obstet Gynecol 174: 754-759, 1996.
 
29) Kaga N, Katsuki Y, Futamura Y et al.: Role of urinary trypsin inhibitor in the maintenance of pregnancy in mice. Obstet Gynecol 88: 872-882, 1996.
PubMed
30) Kaga N, Katsuki Y, Kajikawa S et al.: Preventive effect of ritodrine hydrochloride and/or urinary trypsin inhibitor against lipopolysaccharide-induced preterm delivery in mice. Acta Obstet Gynecol Scand 76: 811-816, 1997.
PubMed
31) Machnicki M, Zimecki M, Zagulski T: Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin-6 in vivo. Int J Exp Pathol 74: 433-438, 1993.
PubMed
32) Zhang GH, Mann DM, Tsai CM: Neutralization of endotoxin in vivo and in vivo by a human lactoferrin-derived peptide. Infect Immun 67: 11353-1358, 1999.
 
33) Kanayama N, el Maradny E et al.: Urinary trypsin inhibitor suppresses premature cervical ripening. Eur J Obstet Gynecol Reprod Biol 60: 181-186, 1995.
PubMed

[シンポジウム2]

P.28 掲載の参考文献
1) Yamano E, Miyauchi M, Furusyo H, Kawazoe A, Ishikado A, et al.: Inhibitory effects of orally administrated liposomal bovine lactoferrin on the LPS-induced osteoclastogenesis. Lab Invest 90: 1236-1246, 2010.
PubMed
2) Ishikado A, Uesaki S, Suido H, Nomura Y, Sumikawa K, et al.: Human trial of liposomal lactoferrin supplementation for periodontal disease. Biol Pharm Bull 33: 1758-1762, 2010.
PubMed
3) Haversen L, Ohlsson B G, Hahn-Zoric M, Hanson L A, Mattsby-Baltzer I: Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 220: 83-95, 2002.
PubMed
4) Machnicki M, Zimecki M, Zagulski T: Lactoferrin regulates the release of tumor necrosis factor α and interleukin 6 in vivo. Int J Exp Pathol 74: 433-439, 1993.
 
5) Appelmelk B J, An Y Q, Geerts M, Thijs B G, de Boer HA, MacLaren D M, de Graaff J, Nuijens J H: Lactoferrin is a lipid A-binding protein. Infect Immun 62: 2628-2632, 1994.
PubMed
6) Elass-Rochard E, Legr D, Salmon V, Roseanu A, Trif M, et al.: Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 66: 486-491, 1998.
 
7) Hayden M S, Ghosh S: Shared principles in NF-kB signaling. Cell 132: 344-362, 2008.
PubMed
8) Tak P P, Firestein G S: NF-kB: akey role in inflammatory diseases. J Clin Invest 107-: 7-11, 2001.
 
9) Jimi E Aoki K, Saito H, D'Acquisto F, May M J. et a.: Selective inhibition of NF-k B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10: 617-624, 2004.
 
10) Karin, Ben-Neriah Y: Phosphorylation meets ubiquitination. The control of NF-kB activity. Annu Rev Immunol 18: 621-663, 2000.
PubMed
11) Sun L, Deng L, Ea C K, Xia Z P, Chen ZJ: The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in lymphocytes. Mol Cell 2004 14: 289-301, 2004.
PubMed
12) Deng L, Wang C, Spencer E, Yang L, Braun A, et al.: Activation of the lkB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103: 351-361, 2000.
 
P.34 掲載の参考文献
1) Duarte DC, Nicolau A, Teixeira JA, Rodrigues LR: The effect of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci 94(1): 66-76, 2011.
PubMed
2) Ivanov AA, Ulanova AM, Stavrakova NM, Deshevoi IuB, Nasonova TA et al.: Antiradiation effects of lactoferrin. Radiats Biol Radioecol 49(4): 456-461, 2009.
PubMed
3) Wen P, Guo H, Zhang H, Gan B, Ding Q, Ren F: Effect of glucose on the lactoferrin's conformation and its effect on MC3T3-E1 cell proliferation. Protein J 31(4): 300-305, 2012.
 
4) Allaeys I, Rusu D, Picard S, Pouliot M, Borgeat P, Poubelle PE: Osteoblast retraction induced by adherent neutrophils promotes osteoclast bone resorption: implication for altered bone remodeling in chronic gout. Lab Invest 91(6): 905-920, 2011.
PubMed
5) Naot D, Grey A, Reid IR, Cornish J: Lactoferrin-a novel bone growth factor. Clin Med Res 3(2): 93-101, 2005.
PubMed
6) Harrison G, Shapiro IM, Golub EE: The phosphatidylinositol-glycolipid anchor on alkaline phosphatase facilitates mineralization initiation in vitro. J Bone MinerRes 10(4): 568-573, 1995.
PubMed
7) Addison WN, Azari F, Sorensen ES: Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 282(21): 15872-15883, 2007.
PubMed
8) Wang D, Liao X, Qin X, Shi W, Zhou B: A novel chimeric peptide binds MC3T3-El cells to titanium and enhances their proliferation and differentiation. Mol Med Rep 7(5): 1437-1441, 2013.
 
9) Komori T: Regulation of osteoblast differentiation by Runx2. Adv Exp Med Biol 658: 43-49, 2010.
PubMed
10) Zhang C, Cho K, Huang Y, Lyons JP, Zhou X. et al.: Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc Natl Acad Sci USA 105(19): 6936-6941, 2008.
 
11) Huihua Fu, Bruce Doll, Tim McNelis, Jeffrey O Hollinger: Osteoblast differentiation in vitro and in vivo promoted by Osterix. J Biomed Mater Res A 83(3): 770-778, 2007.
PubMed
P.39 掲載の参考文献
1) Cornish J: Lactoferrin promotes bone growth. Biometals 7: 331-335, 2004.
 
2) Guo HY, Jiang L, Ibrahim SA, Zhang L, Zhang H et al.: Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats. J Nutr 139: 958-964. 2009.
 
3) Cornish J, Callon K. E, Naot D, Palmano K. P, Banovic Tet al.: Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology 145: 4366-4374, 2004.
 
4) Takayama Y, Mizumachi K, : Effect of lactoferrin-embedded collagen membrane on ostogenic differentiation of human osteoblastic-like cells. J Biosci Bioeng 107: 191-195, 2009.
 
5) Baveye S, Elass E, Mazurier J, Spik G, Legrand D: Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med 37: 281-286, 1999.
PubMed
6) Boch C, Melsen B, Vargervik K: Importance of the critical-size bone defect in testing bone regeneration. J Craniofac Surg 9: 310-316. 1998.
 
7) Takaoka R, Hikasa H, Hayashi K, Tabata Y: Bone regeneration by lactoferrin released from a gelatinhydrogel. J Biomate Sci 22: 1581-1589, 2011.
 
8) Mountziaris P. M, Mikos A. G: Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng Part B Rev 14: 179-186, 2008.
PubMed

[一般演題およびポスターセッション]

P.49 掲載の参考文献
1) Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD et al.: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77: 7415-7419, 1981.
 
2) Reitz MS, Poiesz B, Ruscetti FW, Gallo RC: Characterization and distribution of nucleic acid sequence of a novel type C retrovirus isolated from neoplastic human T lymphocytes. Proc Natl Acad Sci USA 78: 1887-1891, 1981.
 
3) Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H: Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50(3): 481-492, 1977.
PubMed
4) Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T et al.: Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78(10): 6476-6480, 1981.
 
5) Watanabe T: HTLV-1-associated diseases. Int J Hematol 66(3): 257-278, 1997.
PubMed
6) 田中正和, 鄭真美, 長谷川翔, 和田直樹・他: ウシラクトフェリンによるHTLV-1抗腫瘍効果. ラクトフェリン2011. 日本医学館, 2011, p14-20.
 
7) 久原徹哉: ラクトフェリンによる腸上皮からのIL-18産生誘導とその意義. 臨床免疫 34: 376-381, 2000.
 
8) Ishii K, Matshmaru K, Takamura N, Shinohara M, Shinohara M et al.: Bovine lactoferrin induces serum IL-18 in patients with chronic hepatitis. J Med Soc Toho 51: 214-221, 2004.
 
9) Furuta RA, Sugiura K, Kawakita S, Inada T, Ikehara Set al.: Mouse model for the equilibration interaction between the host immune system and human T-cell leukemia virus type 1 gene expression. J Virol 76(6): 2703-2713, 2002.
 
10) Kuhara T, Yamauchi K, Tamura Y, Okamura H: Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interferon Cytokine Res 26: 489-499, 2006.
PubMed
P.53 掲載の参考文献
1) Kaido M, Ishida R, Dogru M, Tsubota K: Visual function changes after punctal occlusion with the treatment of short BUT type of dry eye. Cornea 31: 1009-1013, 2012.
PubMed
2) Tsubota K, Nakamori K: Dry eyes and video display terminals. N Engl J Med 328: 584, 1993.
PubMed
3) Uchino M, Schaumberg DA, Dogru M, Uchino Y, Fukagawa K et al.: Prevalence of dry eye disease among Japanese visual display terminal user. Ophthalmology 115: 1982-1988, 2008.
 
4) Nakamura S, Kinoshita S, Yokoi N, Ogawa Y, Shibuya M et al.: Lacrimal hypofunction as a new mechanism of dry eye in visual display terminal users. PLoS One 5: e11119, 2010.
PubMed
5) Kawashima M, Kawakita T, Inaba T, Okada N, Ito M et al.: Dietary lactoferrin alleviates age-related lacrimal gland dysfunction in mice PLoS One 7: e33148, 2012.
PubMed
6) Nakamura S, Shibuya M, Nakashima H, Imagawa T, Uehara M et al.: D-beta-hydroxybutyrate protects against corneal epithelial disorders in a rat dry eye model with jogging board. Invest Ophthalmol Vis Sci 46: 2379-2387, 2005.
 
7) Nakamura S, Shibuya M, Nakashima H, Hisamura R, Masuda N et al.: Involvement of oxidative stress on corneal epithelial alterations in a blink-suppressed dry eye. Invest Ophthalmol Vis Sci 48: 1552-1558, 2007.
 
8) Kamemori N, Takeuchi T, Hayashida K, Harada E: Suppressive effects of milk-derived lactoferrin on psychologicai stress in adult rats. Brain Res 1029: 34-40, 2004.
PubMed
P.59 掲載の参考文献
1) Suzuki YA, Lonnerdal B: Lactoferrin: structure, functions, and applications. Funct Food Rev 2: 69-79, 2010.
 
2) 平田善彦: 抗菌技術への取り組みの現状課題(1)環境浄化薬剤(5)バイオサーファクタント(ソホロリピッド)の工業的生産と洗浄剤への応用. 防菌防黴 39: 261-267, 2011.
 
3) Scholz C, Mehta S, Bishit K, Guilmanov V, Kaplan D et al.: Bioactivity of extracellular glycolipids investigation of potential anticancer activity of sophorolipids and sophorolipid derivatives. Polymer Prep 39: 168-169, 1998.
 
4) Chen J, Song X, Zhang H, Qu Y B, Miao J Y: Sophorolipid produced from the new yeast strain Wickerhamiella domercqiae induces apotosis in H7402 human liver cancer cells. Appl Microbiol Biotechnol 72: 52-59, 2006.
 
5) Shah V, Doncel G F, Seyoum T, Eaton K M, Zalenskaya I et al.: Sophorolipids, microbial glycolipis with anti-human immunodeficiency virus and spermimmobilizing activities. Antimicrob Agents Chemother 49: 4093-4100, 2005.
 
6) Ishii N, Kobayashi T, Matsumiya K, Ryu M, Hirata Y et al.: Transdermal administration of Lactoferrin with sophorolipid. Biochem Cell Biol 90: 504-512, 2012.
PubMed
7) Saito S, Takayama Y, Mizumachi K, Suzuki C: Lactoferrin promotes hyaluronan synthesis in human dermal fibroblasts. Biotechnol Lett 33: 33-39, 2011.
PubMed
8) 輪千浩史: 糖尿病誘発マウスにおけるラクトフェリンの創傷治癒促進効果. ラクトフェリン2009. 日本医学館 2009. p46-54.
 
P.63 掲載の参考文献
1) 日本消化器病学会編: クローン病診療ガイドライン. 南江堂, 2010, p2～4.
 
2) 武林 亨: 難治性炎症性腸管障害の罹患, 有病, 予後に関する疫学研究. 厚生労働省難治性炎症性腸管障害に関する調査研究班平成18年度報告書 2007.
 
3) Togawa J, Nagase H, Tanaka K, Inamori M, Umezawa T et al.: Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J physiol Gastrointest Liver Physiol 283: G187-G195, 2002.
PubMed
4) Moris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR et al.: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96: 795-803, 1989.
 
5) James DL: The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease. Gastroenterology 140: 1817-826, 2011.
 
6) Ono T, Murakoshi M, Suzuki N, Iida N, Ohdera M et al.: Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr 104(11): 1688-1695, 2010.
PubMed
P.68 掲載の参考文献
1) Albera E, Kankofer M: Antioxidants in colostrums and milk of sows and cows. Reprod Dom Anim 44: 606-611. 2009.
 
2) Chirino Y, Chaverri J: Role of oxidative and nitrosative stress in cisplatine-induced nephrotoxicity. Exp Toxic Pathol 61: 223-242, 2009.
 
3) Cornelison TL, Reed E: Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50: 147-158, 1993.
PubMed
4) Dobyan DC, Levi J, Jacobs C, Kosek K, Weiner MW: Mechanism of cis-platinum nephrotoxicity: II. morphorogic observations. J pharm Exp ther 213: 551-556, 1980.
 
5) Hadaker WT, Stone RA, Mccoy R: Platinum nephrotoxicity. Cancer 34: 1030-1032, 1974.
 
6) Hayashida K, Takeuchi T, Ozaki T, Shimizu H, Ando K, Miyamoto A, Harada E: Bovine lactoferrin has a nitric oxide-dependent hypotensive effect in rats. AJP-Regul Integr Comp Physiol 284: R359-R365, 2003.
 
7) Kawai Y: Involvement of intraceelluar calcium and reactlve oxygen species in an antitumor agent cisplatin-induced nephrotoxicity. Osaka uni Phamaceu sci 1: 129-134, 2006.
 
8) Kruidering M, Vanwater B, Heer E, Mulder GJ, Nagellerke JF: Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280: 638-49, 1997.
 
9) Lee HB, Blaufox MD: Renal functional response to captopril during diuretic therapy. J Nucl Med 33: 739-7431992.
PubMed
10) Pabla N, Dong Z: Cispaltin nephrotoxicity: Mechanisms and renoprotective strategies. Kid Intern 73: 994-1007, 2008.
 
11) Satue'-Gracia MT, Frankel EN, Rangavajhyala N, German JB: Lactoferrin in infant formulas: effect on oxidation. J Agric Food Chem 48: 4984-4990, 2000.
PubMed
12) Togawa J, Nagase H, Tanaka K, Inamori M, Umezawa T, Nakajima A, Naito M, Sato S, Saito T, Sekihara H: Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J physiol Gastrointest Liver Physiol 283: Gl87-195, 2002.
PubMed
13) Vickers AE, Rose K, Fiser R, Sauinier M, Sahota P, Bentley P: Kidney slices of human and rat characterize cisplatin-induced injury on cellular pathway and morphology. Toxicol pathol 32: 577-590, 2004.
 
14) Winston JA, Safirsten R: Reduced renal blood flow in early cisplatin-induced acute failure in the rat. Am J Physiol 249: 490-496, 1985.
 
P.72 掲載の参考文献
1) 森 泰胤・他: ニカラベンの放射線防護剤としての有用性の検討-マウス生存率, 脾コロニー, 末梢血液像, 脂質過酸化について-. 岡山医学会雑誌 105: 673-680, 1993.
 
2) 長谷川武夫・他: 放射線防護剤および放射線増感剤に関する研究. 鈴鹿医療科学大学紀要 9: 87-96, 2002.
 
3) 西村義一・他: マウスに対するラクトフェリンの放射線防護効果. ラクトフェリン2007. (第2回ラクトフェリンフォーラム実行委員会・編), 日本医学館, 東京, 2007, p56-59.
 
4) Shimada Y et al.: Genetic susceptibility to thymic lymphomas and K-ras gene mutation in mice after exposurc to X-rays and N-ethyl-N-nitrosourea. Int J Radiat Biol Jun 79(6): 423-430, 2003.
 
5) Hirano S et aL: Ikaros is a critical target during simultaneous exposure to X-rays and N-ethyl-N-nitrosourea in mouse T-cell lymphomagenesis. Int J Cancer Jan 15 132(2): 259-268, 2013.
 
6) 飯郷正明・他: ウシラクトフェリンによるがん予防の基礎と大腸腺腫進展抑制効果. ラクトフェリン2009. (第3回ラクトフェリンフォーラム実行委員会・編), 日本医学館, 東京, 2009, p32-37.
 
P.78 掲載の参考文献
1) 総務省: 「国勢調査」および「人口推計」, 国立社会保障・人口問題研究所「日本の将来推計人口(平成24年1月推計)」
 
2) Garcia-Montoya I A, Cendon T S, Arevalo-Gallegos, S, and Rascon-Cruz Q: Lactoferrin, a multiple bioactive protein, an overview. Biochim Biophys Acta 1820: 226-236, 2012.
 
3) Clare D A, Catignani G L, Swaisgood H E: Biodefense properties of milk, the role of antimicrobial proteins and peptides. Curr Pharm Des 9: 1239-1255, 2003.
 
4) Jenssen H, Hancock R E: Antimicrobial properties of lactoferrin. Biochimie 91: 19-29, 2009.
 
5) Baveye S, Elass E, Mazurier J, Spik G, Legrand D: Lactoferrin, a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med 37: 281-286, 1999.
PubMed
6) Knuzel M L, Harari Y, Mailman D, Actor J K, Zimecki M: Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol 130: 25-31, 2002.
 
7) Shau H Kim A, Golub S H: Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leukoc Biol 51: 343-349, 1992.
PubMed
8) Damiens E, Mazurier J, el Yazidi I, Masson M, Duthille I et al.: Effect of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells. Biochim Biophys Acta 1402: 277-287, 1998.
PubMed
9) Miyauchi H, Hashimoto S, Nakajima M, Shinoda I, Fukuwatari Y. et al.: Bovine lactoferrin stimulates the phagocytic activity of human neutrophils, identification of its active domain. Cell Immunol 187: 34-37, 1998.
PubMed
10) Kawai K, Shimazaki K, Higuchi H, Nagahata H: Antibacterial activity of bovine lactoferrin hydrolysate against mastitis pathogens and its effect on superoxide production of bovine neutrophils. Zoonoses Public Health 54: 160-164, 2007.
PubMed
11) Ward P P, Mendoza-Meneses M, Park P W, Conneely OM: Stimulus-dependent impairment of the neutrophil oxidative burst response in lactoferrin-deficient mice. Am J Pathol 172: 1019-1029, 2008.
PubMed
12) Sorimachi K, Akimoto K, Hattori Y, Ieiri T, Niwa A: Activation of macrophage by lactoferrin, secretion of TNF-α. IL-8 and NO. Biochem. Mol Biol Int 43: 79-87, 1997.
 
13) Puddu P, Carollo M G, Belardelli F. Valenti P, Gessani S: Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages. J Leukoc Biol 82: 347-353, 2007.
PubMed
14) 川上 浩: 生体内に受容体をもつ乳タンパク質の生物学的意義. ミルクサイエンス 61: 125-140, 2012.
 
15) 元売睦美, 吉瀬蘭エミリー, 松山博昭, 細谷知広, 川上 浩・他: ラクトフェリン可溶化鉄が成人女性の貧血指標に及ぼす影響. 日本食品科学工学会誌 54: 442-446, 2007.
 
16) Rosalba R, Torcia F, Berlutti F, Pacifici E, Ebano V et al.: Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem Cell Biol 84: 377-380, 2006.
 
17) Manzoni P, Tarnow-Mordi W, Franco C, Gallo E, Spera A M et al.: Clinical use of lactoferrin in preterm neonates, an update. Minerva Pediatr 62: 101-104, 2010.
PubMed
18) Kozu T, Iinuma G, Ohashi Y, Saito Y, Akasu T et al.: Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res 2: 975-983, 2009.
 
19) Mulder A M, Connellan P A, Oliver C J, Morris A M, Stevenson L M: Bovine lactoferrin supplementation supports immune and antioxidant status in healthy human males. Nutr Res 28: 583-589, 2008.
 
20) Ishikado A, Imanaka H, Kotani M, Fujita A, Mitsuishi Y et al.: Liposomal lactoferrin induced significant increase of the interferon-αproducibility in healthy volunteers. BioFactors 21: 69-72, 2004.
 
21) Bharadwaj A, Naidu, T. A. G, Betageri G. V, Prasadarao N V, Naidu A S: Inflammatory responses improve with milk ribonuclease enriched lactoferrin supplementation in postmenopausal women. Inflamm Res 59: 971-978, 2010.
 
22) Kawakami H, Lonnerdal B: Isolation and function of a receptor for human lactoferrin in human fetal intestinal brush-border membranes. Am J physiol 261: G841-G846, 1991.
PubMed
P.84 掲載の参考文献
1) Ono T, Murakoshi M, Suzuki N, Iida N, Ohdera M et al.: Br J Nutr 104: 1688-1695, 2010.
PubMed
2) Ono T, Morishita S, Fujisaki C, Ohdera M, Murakoshi Metal.: Br J Nutr 105: 200-211, 2011.
 
3) Falck-Ytter, Y. Younossi Z M, Marchesini G, McCullough A J: Semin Liver Dis 21: 17-26, 2001.
PubMed
4) Fischer R, Debbabi H, Blais A, Dubarry M, Rautureau M et al.: Int Immunopharmacol 7: 1387-1393, 2007.
PubMed
5) Ziere G J, van Dilk M C, Bijsterbosch M K, van Berkel T J:J Biol Chem 267: 11229-11235, 1992.
 
6) Lin C L, Huang H C, Lin J K: J Lipid Res 48: 2334-2343, 2007.
PubMed
7) Eskes R, Antonsson B, Osen-Sand A, Montessuit S, Richter C et al.: J Cell Biol 143: 217-224, 1998.
 
8) Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S et al.: EMBO J 23: 1889-1899, 2004.
PubMed
9) Gardai S J, Hildeman D A, Frankel S K, Whitlock, B B, Frasch S C et al.: J Biol Chem 279: 21085-21095, 2004.
PubMed
10) Grey A, Zhu Q, Watson M, Callon K, Cornish J: Mol Cell Endocrinol 251: 96-102, 2006.
PubMed
P.90 掲載の参考文献
1) Farnaud S, Evans RW: Lactoferrin-a multifunctional protein with antimicrobial properties. Mol Immunol 40: 395-405, 2003.
PubMed
2) Rahman MM, Kim WS, Kumura H, Shimazaki K: Screening of Bifidobacterium spp. based on in vitro growth responses to bovine lactoferrin. Int J Food Sci Technol 45: 453-458, 2010.
 
3) Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K et al.: Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta 1121: 130-136, 1992.
PubMed
4) Liepke C, Adermann K, Raida M, Magert HJ, Forssmann WG et al.: Human milk provides peptides highly stimulating the growth of bifidobacteria. Eur J Biochem 269: 712-718, 2002.
PubMed
5) Dionysius DA, Milne JM: Antibacterial peptides of bovine lactoferrin: purification and characterization. J Dairy Sci 80: 667-674, 1997.
PubMed
6) 光岡知足: 腸内菌叢研究の歩み. 腸内細菌学雑誌 25: 113-124, 2011.
Medical*Online
7) Oda H, Wakabayashi H, Yamauchi K, Sato T, Xiao JZ et al.: Isolation of a bifidogenic peptide from the pepsin hydrolysate of bovine lactoferrin. Appl Environ Microbiol 79: 1843-1849, 2013.
PubMed
P.95 掲載の参考文献
1) Vogel H J: Lactoferrin, a bird's eye view. Biochem Cell Biol 90: 233-244, 2012.
 
2) Kodera Y, Tanaka H, Matsushima A, Inada Y: Chemical modification of L-asparaginase with a comb-shaped copolymer of polyethylene glycol derivative and maleic anhydride. Biochem Biophys Res Commun 184: 144-148, 1992.
PubMed
3) Bailon P, Palleroni A, Schaffer C A, Spence C L, Fung W J et al.: Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12: 195-202, 2001.
PubMed
4) Nojima Y, Suzuki Y, Iguchi K, Shiga T, Iwata A et al.: Development of poly(ethylene glycol)conjugated lactoferrin for oral administration. Bioconjug Chem 19: 2253-2259, 2008.
 
5) Nojima Y, Suzuki Y, Yoshida K, Abe F, Shiga T et al.: Lactoferrin conjugated with 40-kDa branched poly(ethylene glycol)has an improved circulating half-life. Pharm Res 26: 2125-2132, 2009.
PubMed
6) Nojima Y, Iguchi K, Suzuki Y, Sato A: The pH- dependent formation of PEGylated bovine lactoferrin by branched polyethylene glycol(PEG)-N-hydroxysuccinimide(NHS)active esters. Biol Pharm Bull 32: 523-526, 2009.
 
7) Kato K, Tamaki N, Saito Y, Fujimoto T, Sato A, : Amino group PEGylation of bovine lactoferrin by linear polyethylene glycol-p-nitrophenyl active esters. Biol Pharm Bull 33: 1253-1255, 2010.
PubMed
8) Anderson B F, Baker H M, Norris G E, Rumball S V, Baker E N: Apolactoferrin structure demonstrates ligand-induced conformational change in transferrins. Nature 344: 784-787, 1990.
PubMed
9) Mattsby-Baltzer I, Roseanu A, Motas C, Elverfors J, Engberg I et al. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 40: 257-262, 1996.
 
10) Takeuchi T, Kitagawa H, Harada E: Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol. 89: 263-270, 2004.
PubMed
P.100 掲載の参考文献
1) Takeuchi T, Kitagawa H, Harada E: Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89: 263-270, 2004.
PubMed
2) Ashida K, Sasaki H, Suzuki Y A, Lonnerdal B: Cellular internalization of lactoferrin in intestinal epithelial cells. BioMetals 17: 311-315, 2004.
PubMed
3) Suzuki Y A, Wong H, Ashida K, Schryvers A B, Lonnerdal B: The N1 Domain of Human Lactoferrin is Required For Internalization By Caco-2 Cells and Targeting to the Nucleus. Biochemistry 47: 10915-10920, 2008.
 
4) Nojima Y, Suzuki Y, Iguchi K, Shiga T, Iwata A et al.: Development of poly(ethylene glycol)conjugated lactoferrin for oral administration. Bioconjug Chem 19: 2253-2259, 2008.
 
5) Hara K, Suda T, Suda J, Eguchi M, Ihle J N et al.: Bipotential murine hemopoietic cell line(NFS-60)that is responsive to IL-3, GM-CSF, G-CSF, and erythropoietin. Exp Hematol 16: 256-261, 1988.
PubMed
6) Jiang R, Lopez V, Kelleher S L, Lonnerdal B: Apoand holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. J Cell Physiol 226: 3022-3031, 2011.
 
7) Suzuki Y A, Shin K, Lonnerdal B: Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 40: 15771-15779, 2001.
PubMed
8) Conesa C, Pocovi C, Perez M D, Calvo M, Sanchez L: Transport of iron bound to recombinant human lactoferrin from rice and iron citrate across Caco-2 cell monolayers. Biosci Biotechnol Biochem 73: 2615-2620, 2009.
 
9) Akiyama Y, Oshima K, Shin K, Wakabayashi H, Abe F et al.: Intracellular Retention and Subsequent Release of Bovine Milk Lactoferrin Taken Up by Human Enterocyte-Like Cell Lines, Caco-2, C2BBel and HT-29. Biosci Biotechnol Biochem 77: 1023-1029, 2013.
 
P.109 掲載の参考文献
1) Baker EN, Baker HM: A structural framework for understanding the multifunctional character of lactoferrin. Biochimie 91: 3-10, 2009.
PubMed
2) Masson PL, Heremans JF: Lactoferrin in milk from different species. Comp Biochem Physiol B39: 119-129, 1971.
 
3) Lonnerdal B, Iyer S: Lactoferrin: molecular structure and biological function. Annu Rev Nutr 15: 93-110, 1995.
PubMed
4) Liao Y, Jiang R, Lonnerdal B: Biochemical and molecular impacts of lactoferrin on small intestinal growth and development during early life. Biochem Cell Biol 90: 476-484, 2012.
PubMed
5) Brock JH: The physiology of lactoferrin. Biochem Cell Biol 80: 1-6, 2002.
PubMed
6) Iigo M, Shimamura M, Matsuda E, Fujita K, Nomoto H et al.: Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa: a possible explanation for inhibition of carcinogenesis and metastasis. Cytokine 25: 36-44, 2004.
PubMed
7) Kuhara T, Yamauchi K, Tamura Y, Okamura H: Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interferon Cytokine Res 26: 489-499, 2006.
PubMed
8) Ono T, Murakoshi M, Suzuki N, Iida N, Ohdera M et al.: Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr 104: 1688-1695, 2010.
PubMed
9) Takeuchi T, Shimizu H, Ando K, Harada E: Bovine lactoferrin reduces plasma triacylglycerol and NEFA accompanied by decreased hepatic cholesterol and triacylglycerol contents in rodents. Br J Nutr 91: 533-538, 2004.
PubMed
10) Ward PP, Uribe-Luna S, Conneely OM: Lactoferrin and host defense. Biochem Cell Biol 80: 95-102, 2002.
PubMed
11) Wakabayashi H, Kuwata H, Yamauchi K, Teraguchi S, Tamura Y: No detectable transfer of dietary lactoferrin or its functional fragments to portal blood in healthy adult rats. Biosci Biotechnol Biochem 68: 853-860, 2004.
PubMed
12) Gislason J, Douglas GC, Hutchens TW, Lonnerdal B: Receptor-mediated binding of milk lactoferrin to nursing piglet enterocytes: a model for studies on absorption of lactoferrin-botlnd iron. J pediatr Gastroenterol Nutr 21: 37-43, 1995.
 
13) Suzuki YA, Shin K, Lonnerdal B: Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 40: 15771-15779, 2001.
PubMed
14) Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A et al.: Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 276: 23456-23463, 2001.
PubMed
15) Wrackmeyer U, Hansen GH, Seya T, Danielsen EM: Intelectin: anovel lipid raft-associated protein in the enterocyte brush border. Biochemistry 45: 9188-9197, 2006.
 
16) Mikogami T, Heyman M, Spik G, Desjeux JF: Apical-to-basolateral transepithelial transport of human lactoferrin in the intestinal cell line HT-29cl. 19A. Am J Physiol 267: G308-G315, 1994.
PubMed
17) Jiang R, Lopez V, Kelleher SL, Lonnerdal B: Apo-and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. J Cell Physiol 226: 3022-031, 2011.
PubMed
18) Shin K, Wakabayashi H, Yamauchi K, Yaeshima T, Iwatsuki K: Recombinant human intelectin binds bovine lactoferrin and its peptides. Biol Pharm Bull 31: 1605-1608, 2008.
PubMed
19) Lonnerdal B, Jiang R, Du X: Bovine lactoferrin can be taken up by the human intestinal lactoferrin receptor andexert bioactivities. J pediatr Gastroenterol Nutr 53: 606-614, 2011.
PubMed
20) Akiyama Y, Oshima K, Shin K, Wakabayashi H, Abe F et al.: Intracellular retention and subsequent release of bovine milk lactoferrin taken up by human enterocyte-like cell lines, Caco-2, C2BBel and HT-29. Biosci Biotechnol Biochem 77: 1023-1029, 2013.
 
21) Akiyama Y, Oshima K, Kuhara T, Shin K, Abe F et al.: A lactoferrin-receptor, intelectin 1, affects uptake, subcellular localization and release of immunochemically detectable lactoferrin by intestinal epithelial Caco-2 cells. J Biochem 2013 doi: 10. 1093/jb/mvt073.
 
P.114 掲載の参考文献
1) Wakabayashi H, Kondo I, Kobayashi T, Yamauchi K, Toida T et al.: Periodontitis, periodontopathic bacteria and lactoferrin. Biometals 23: 419-424, 2010.
PubMed
2) Shin K, Horigome A, Wakabayashi H, Yamauchi K, Yaeshima T et al.: In vitro and in vivo effects of a composition containing lactoperoxidase on oral bacteria and breath odor. J Breath Res 2: 017014(5pp), 2008.
 
3) Shin K, Yaegaki K, Murata T, Ii H, Tanaka T et al.: Effects of a composition containing lactoferrin and lactoperoxidase on oral malodor and salivary bacteria: arandomized, double-blind, crossover, placebo-controlled clinical trial. Clin Oral Invest 15: 485-493, 2011.
 
4) 小林哲夫, 清水英寿, 若林裕之, 山内恒治, 岩附慧二. 他: ウシラクトフェリン + ラクトパーオキシダーゼ配合錠菓摂取による歯肉炎への影響. ラクトフェリン2011, 日本医学館, 2011, p21-26.
 
5) 清水英寿, 若林裕之, 小林哲夫, 吉江弘正: 歯周病患者におけるラクトフェリン + ラクトパーオキシダーゼ錠菓摂取による体感効果. 日本歯科東洋医学会誌 30: 1-7, 2011.
 
6) Takeshita T, Nakano Y, Yamashita Y: Improved accuracy in terminal restriction fragment length polymorphism phylogenetic analysis using a novel internal size standard definition. Oral Microbiol Immunol 22: 419-428, 2007.
PubMed
7) 松木隆広: ヒト腸内フローラ構成菌の定量的PCR検出法の確立および菌属・菌種分布の解析. 日本細菌学雑誌 62: 255-261, 2007.
Medical*Online
8) Almstahl A, Wikstrom M, Groenink J: Lactoferrin, amylase and mucin MUC5B and their relation to the oral microflora in hyposalivation of different origins. Oral Microbiol Immunol 16: 345-352, 2001.
 
9) Arslan SY, Leung KP, Wu CD: The effect of lactoferrin on oral bacterial attachment. Oral Microbiol Immunol 24: 411-416, 2009.
PubMed
10) Courtois PH, Majerus P, Labbe M, Abbeele AV, Yourassowsky E et al.: Susceptibility of anaerobic microorganisms to hypothiocyanite produced by lactoperoxidase. Acta Stomatol Belg 89: 155-162, 1992.
 
11) Ihalin R, Loimaranta, V. Lenander-Lumikari M, Tenovuo J: The sensitivity of Porphyromonas gingivalis and Fusobacterium nucleatum to different(pseudo)halide-peroxidase combinations compared with mutans streptococci. J Med Microbiol 50: 42-48, 2001.
PubMed
12) Kolenbrander PE, Andersen RN, Blehert DS, Egland PG, Foster JS et al.: Communication among oral bacteria. Microbiol Mol Biol Rev 66: 486-505, 2002.
PubMed
13) Roberts GL: Fusobacterial infections: an underestimated threat. Br J Biomed Sci 57: 156-162, 2000.
PubMed
14) Koren O, Spor A, Felin J, Fak F, Stombaugh J et al.: Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA 108: 4592-4598, 2011.
PubMed
P.119 掲載の参考文献
1) Verani J R, Lorick S A, Yoder J S, Beach M J, Braden CR et al.: National outbreak of Acanthamoeba keratitis associated with use of a contact lens solution, United States. Emerging Infect Dis 15: 1236-1242, 2009.
PubMed
2) 国民生活センター: ソフトコンタクトレンズ用消毒剤のアカントアメーバに対する消毒性能-使用実態調査も踏まえて-. 2009.
 
3) Matsue M, Tomita S, Nyui S, Matsuyama J, Kiyosawa I: Suppressive effects of lactoferrin on bleomycin-dependent DNA damage by the iron ion and ascorbate. Biosci Biotechnol Biochem 58: 67-71, 1994.
 
4) Kobayashi T, Gibbon L, Mito T, Shiraishi A, Uno T et al.: Efficacy of commercial soft contact lens disinfectant solutions against Acanthamoeba. Jpn J Ophthalmol 55: 547-557, 2011.
PubMed
5) Kilvington S, Heaselgrave W, Lally J M, Ambrus K, Powell H: Encystment of Acanthamoeba during incubation in multipurpose contact lens disinfectant solutions and experimental formulations. Eye Contact Lens 34: 133-139, 2008.
PubMed
6) Connell C, Rutter A, Hill B, Suller M, Lloyd D: Encystation of Acanthamoeba castellanii: Dye uptake for assessment by flow cytometry and confocal laser scanning microscopy. J Appl Microbiol 90: 706-712, 2001.
PubMed
7) 織田浩嗣, 村田麻衣, 山内恒治: ラクトフェリンの保健機能. 乳業技術 60: 9-22, 2010.
 
8) International Organization for Standardization: ISO 14729: Ophthalmic optics-contact lens care products. Microbiological requirements and test methods for products and regimens for hygienic management of contact lenses, 2001.
 
9) Tomita S, Shirasaki N, Matsuyama J, Benno Y, Kiyosawa I: Growth behavior of Clostridium perfringens cells aggregated by bovine lactoferrin in the presence of lipoteichoic acid. Food Preservation Sci 32: 85-89, 2006.
 
10) 冨田信一, 長谷川祥太, 魚谷孝之, 新本洋士, 小幡博人, 佐々木香る, 東岸和明: ラクトフェリンのアカントアメーバ臨床株における抗アメーバ活性. ラクトフェリン2011. (日本ラクトフェリン学会第4回学術集会実行委員会・編), 日本医学館, 東京, 2011, p35-40.
 
11) 今安正樹: Multi Purpose Solutionの抗菌活性に関する新しい知見について教えてください. あたらしい眼科 26: 238-240, 2009.
 
P.125 掲載の参考文献
1) 吉ざわ努, 平子 誠, 下司雅也, 高橋昌志, 永井 卓: 牛の人工授精における繁殖性の現状(アンケート調査から考える原因と対策). 畜産技術 659: 2-6, 2010.
 
2) 平子 誠: 乳牛の繁殖性が低下する原因について. 畜産技術 659: 7-11, 2010.
 
3) Butler WR: Effect of protein nutrition on ovarian and uterine physiology in dairy cattle. Journal of Dairy Science 81: 2533-2539, 1998.
PubMed
4) Ametaj BN, Hosseini A, Odhiambo JF, Iqbal S, Sharma S et al.: 13: Application of Acute Phase Proteins for Mouitoring Inflammatory States in Cattle. [Acute phase proteins as early non-specific biomarkers of human and veterinary diseases. ] （ed. Veas F. ), Intech, 2011, p301-354.
 
5) 石井利明, 難波俊二, 奥田優子, 佐野将也, 盛田俊介: 感染症における血中ラクトフェリン測定の有用性について. Milk Science 53: 232-234, 2004.
 
6) 田端一恵: 便中ラクトフェリンと大腸がんの進行度に関する検討. JJCLA 28: 652-656, 2003.
 
7) Hagiwara S, Kawai K, Anri A, Nagahata H: Lactoferrin concentrations in milk from normal and subclinical mastitic cows. Journal of Veterinaly Medical Sciense 65: 319-323, 2003.
 
8) Das SK, Jian J, Johnson DC, Dey SK: Differential spatiotemporal regulation of lactoferrin and progesterone receptor genes on the mouse uterus by primary estrogen, catechol estrogen, and xenoestrogen. Endocrinology 139: 2905-2915, 1998.
 
9) Wared PP, Mendoza-Meneses M, Mulac-Jericevic B, Cunningham GA, Saucedo-Cardenas O et al.: Restricted spatioemporal expression of lactoferrin during murine embryonic development. Endocrinology 140: 1852-1860, 1999.
 
10) Kida K, Baba E, Torii R, Kawate N, Hatoya S et al.: Lactoferrin expression in the canine uterus during the estrous cycle and with pyometra. Theriogenoogy 66: 1325-1333, 2006.
PubMed
11) Hirako M, Takahashi T, Domeki I: Peripheral changes in estrone sulfate ate concentration during the first rimester of gestation in cattle: comparison with unconjugated wstrogens and relationship to fetal number. Theriogenology 57: 1939-1947, 2002.
 
12) Takahashi T, Hirako M, Takahashi H, Patel OV, Takenouchi N et al.: Maternal plasma estrone sulfate ate profile during pregnancy in the cow;comparison between singleton and twin prgnancies. Journal Veterinary Medical Sciense 59: 287-288, 1997.
 
P.130 掲載の参考文献
1) Levay P E. Vilijon M: Lactoferrin: a general review. Haematologica 80: 252-267, 1995.
 
2) Hattsby-Balzer I, Roseanu A, Motas C, Elverforts J, Engberg I et al.: Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 40: 257-262, 1996.
PubMed
3) Chierici R, Sawatzki G, Tamisari L, Volpato S, Vigi V: Supplementation of an adapted formula with bovine lactofferin. 2. Effects on serum iron, ferritin and zinc levels. Acta Paediatr 81: 475-479, 1992.
 
4) Ikeda M, Sugiyama K, Tanaka T, Tanaka T, Tanaka K et al.: Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 245: 549-553, 1998.
PubMed
5) Arnold R R, Brewer M, Gauthier J J: Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. Infect Immun 28: 893-898, 1980.
PubMed
6) Yamaguchi K, Wakabayasi H, Hasimoto S, Teraguchi S, Hayasawa H et al.: Effect of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv Exp Med Biol 443: 261-265, 1998.
 
7) Ambruso D R, Johnston R B Jr: Lactoferrin enhances hydroxyl radical production by human neutrophils, neutrophil particulate fractions, and an enzymatic generating system. J Clin Invest 67: 352-360, 1981.
 
8) Sekine K, Watanabe E, Nakamura J, Takasuka N, Kim D J et al.: Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res 88: 523-526, 1997.
PubMed
9) Kanemori N, Takeuchi T, Hayashida K, Harada E: Suppressive effects of milk-derived lactoferrin on psychological stress in adult rat. Brain res 1029: 34-40, 2004.
 
10) Hayashida K, Takeuchi T, Shimuzu H, Ando K, Harada E: Novel function of bovine milk-derived lactoferrin on antinociception mediated by mu-opioid receptor in the rat spinal cord. Brain Res 965: 239-245, 2003.
 
11) Jazayeri J A, Carroll G J: Fc-Based Cytokines: Prospects for Engineering Superior Therapeutics. Biodrugs 22: 11-26, 2008.
PubMed
12) Dimitrov D S: Engineered CH2 domains(nanoantibodies). mAbs 1: 26-28, 2009.
PubMed
13) Zalevsky J, Chamberlain A K, Horton H M, Karki S, Leung I W et al.: Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28: 157-159, 2010.
PubMed
14) Im S J, Yang S I, Yang S H, Choi D H, Choi S Y et al.: Natural From of Noncytolytic Flexible Human Fc as a Long-Acting Carrier of Agonistic Ligand, Erythropoietin. PloS One 6: e24574, 2011.
PubMed
15) Nojima Y, Suzuki Y, Iguchi K, Shiga T, Iwata A et al.: Development of Poly(ethylene glycol)Conjugated Lactoferrin for Oral Administration. Bioconjug Chem 19: 2253-2259, 2008.
 
16) Ashida K, Sasaki H, Suzuki Y A, Lonnerdal B: Cellular internalization of lactoferrin in intestinal epithelial cells. Biometals 17: 311-315, 2004.
PubMed
17) Tianlei Y, Weizao C, Rui G, Yang F, Dimiter S D: Soluble Monomeric IgG1 Fc. J Biol Chem 286: 19399-19408, 2012.
 
P.134 掲載の参考文献
1) Havard Jenseen, Robert E. W. Hancock: Antimicrobial properties of lactoferrin. Biochimie 91: 19-29, 2009.
 
2) Kim WS, Ohashi M, TanakaT, Kumura H, Kim GY, et al.: Groth-promoting effects of lactoferrin on L. acidophilus and Bifidobacterium sppBiometals (3): 279-283, 2004.
 
3) Artym J: A remedy against obesity? The role of lactoferrin in the metabolism of glucose and liqids. Postepy Hig Med Dosw 22(66): 937-953, 2012.
 
4) 小野知二, 村越倫明: ラクトフェリンによる脂質代謝の制御. 化学と生物 49(1): 15-21, 2011.
 
5) 高山喜晴, ウシラクトフェリンによる骨芽細胞の分化促進と骨組織再生への応用. 畜産技術 639: 2-6, 2008.
 
6) 元賣睦美, 吉瀬蘭エミリー, 松山博昭, 細谷知広, 門岡幸男: ラクトフェリン可溶化鉄が成人女性の貧血指標に及ぼす影響. 日本食品科学工学会誌 54(10): 442-446, 2007.
 
7) Mulder AM, Connellan PA, Oliver CJ, Morris CA, Stevenson LM: Bovine lactoferrin supplementation supports immune and antioxidant status in healthy human males. Nutr Res 28(9): 583-589, 2008.
PubMed
8) Ana Maneva, Borislava Taleva, Lilia Maneva: Lactoferrin-Protector against Oxidative Stress and Regulator of Glycolysis in Human Erythrocytes. Z. Naturforsch 58c 256-262, 2003.
 
9) 宇理須厚雄: 科学的知見に基づく食物アレルギー患者の安全管理とQOL向上に関する研究. 厚生労働科学研究費補助金 健康安全確保総合研究 食品の安心・安全確保推進研究事業, 1-14, 2011.
 
10) 上野川修一: 食品アレルギーとその原因物質. 日本醸造協会雑誌 82(10): 670-675, 1987.
 
11) Shek LP, Bardina L, Castro R, Sampson HA, Beyer K: Humoral and cellular responses to cow milk proteins in patients with milk-induced IgE-mediated and non-IgE-mediated disorders. Allergy 60: 912-919, 2005.
PubMed
12) Docena GH, Fernandez R, Chirdo FG, FOssati CA: Identification of casein as the major allergenic and antigenic protein of cow's milk. Allergy 51: 412-416, 1996.
 
13) Sicherer SH, Sampson HA: Cow's milk protein-specific IgE concentrations in two age groups of milk-allergic children and in children achieving clinical tolerance. Clin Exp Allergy 29: 507-512, 1999.
 
14) Natale M, Bisson C, Monti G, Peltran A, Garoffo LP, Valentini S, et al.: Cow's milk allergens indentification by two-dimensional immunoblotting and mass spectrometry, Mol Nutr Food Res 48: 363-369, 2004.
 
15) 中野泰至, 下条直樹, 森田慶紀, 有馬孝恭, 冨板美奈子. et al.: 牛乳アレルギー患者におけるカゼイン, βラクトグロブリン感作に関する研究. アレルギー 59 (2): 117-122, 2010.
Medical*Online
16) Ana R, Madureira, Claudia I, Pereira, Ana M. P. Gomes, Manuela E. Pintado, F. Xavier Malcata: Bovine whey proteins-Overview on their main biological properties. Food Research International 40(10): 1197-1211, 2007.
 
17) Yoav D. Livney, Milk proteins as vehicles for bioactives, Current Opinion in Colloid & Interface Science 15: 73-83, 2010.
 
18) Fox PF, McSweeney PLH Advanced Dairy Chemistry, Proteins Part A, vol. 1, 3 edn. New York: Kluwer Academic/Plenum Publishers;2003.
 
19) B. Schlatterer, R. Baeker, K. Schlatterer: Improved purification of β-lactoglobulin from acid whey by means of ceramic hydroxyapatite hromatography with sodium fluoride as a displacer. Journal of Chromatography B 807: 223-228, 2004.
 
20) Bramaud C, Aimar P, Daufin G: Thermal isoelectric recipitation of alpha-lactalbumin from a whey protein concentrate: Influence of protein-calcium complexation. Biotechnol Bioeng 47(2): 121-130, 1995.
 
P.139 掲載の参考文献
1) Legend D, Elass E, Carpentier M, Mazurier J Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci 62: 2549-2559, 2005.
 
2) Sorimachi K, Akimoto K, Hattori Y, Ieiri T, Niwa A: Activation of macrophages by lactoferrin: secretion of TNF-alpha, IL-8 and NO. Biochem. Mol Biol Int 43: 79-87 1997.
PubMed
3) Ellison III RT, Giehl T J, LaForce F M: Damage of outer membrane of the enteric Gram-negative bacteria by lactoferrin and transferrin. Infect Immun 56: 2774-2781, 1988.
 
4) Ando K, Hasegawa K, Shindo K, Furusawa T, Fulino T et al.: Human lactoferrin activates NF-kappaB through the Toll-like receptor 4 pathway while it interferes with the lipopolysaccharide-stimulated TLR4 signaling. FEBS J 277: 2051-2066, 2010.
 
5) Lu Y-C, Yeh W-C, Ohashi P S: LPS/TLR4 signal transduction pathway. Cytokine 42: 145-151, 2008.
PubMed
6) Baveye S, Elass E, Fernig D G, BIanquart C, Mazurier, J et al.: Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infect Immun 68: 6519-6525, 2000.
 
7) Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M et al.: Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 66: 486-491, 1998.
PubMed
8) Spik G, Coddeville B, Montreuil J: Comparative study of the primary structures of sero-, lacto-, and ovotransferrin gylycans from different species Biochimie 70: 1459-1469, 1988.
PubMed
9) Iwaki D, Nishitani C, Mitsuzawa H, Hyakushima N, Sano, H et al.: The CD14 region spanning amino acids 57-64 is critical for interaction with the extracellular Toll-like receptor 2 domain. Biochem Biophys Res Commun 328: 173-176, 2005.
PubMed
10) Nakata T, Yasuda M, Fujita M, Kataoka H, Kiura K et al.: CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptor 2 and l without binding to the complex. Cell Microbiol 8: 1899-1909, 2006.
 
11) Kamada N, Hibi T: Pathogenic roles of intestinal macrophages in inflammatory bowel disease. Folia Pharmacol Jpn 133: 186-189, 2009.
 
P.144 掲載の参考文献
1) Alex KD, Pehek EA: Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113: 296-320, 2006.
PubMed
2) Civelli O, Bunzow JR, Grandy DK: Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 33: 281-307, 1993.
PubMed
3) Coppen A: The biochemistry of affective disorders. Br J Psychiatry 113: 1237-1264, 1967.
PubMed
4) Dal-Zotto S, Marti O, Armario A: Influence of single or repeated experience of rats with forced swimming on behavioural and physiological responses to the stressor. Behav Brain Res 114: 175-181, 2000.
 
5) Gerhardt C, van Heerikhuizen H: Functional characteristics of heterologously expressed 5-HT receptors. Eur J pharmacol 334: 1-23, 1997.
PubMed
6) Gingrich JA, Caron MG: Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16: 299-321, 1993.
PubMed
7) Inoue T, Tsuchiya K, Koyama T: Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain. Pharmacol Biochem Behav 49: 911-920, 1994.
PubMed
8) Kamemori N, Takeuchi T, Hayashida K, Harada E: Suppressive effects of milk-derived lactoferrin on psychological stress in adult rats. Brain Res 1029: 34-40, 2004.
PubMed
9) Lucki I: The forced swimming test as a model for core and component behavioral effects antidepressant drugs. Behav Pharmacol 8: 523-532, 1997.
PubMed
10) Matsumoto M, Yoshioka , Togashi H, Tochihara M, Ikeda T et al.: Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J pharmacol Exp Ther 272: 1044-1051, 1995.
PubMed
11) Meltzer HY, Nash JF: Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43: 587-604, 1991.
PubMed
12) Mezadri TJ, Batista GM, Portes AC, Marino-Netoa J, Lino-de-Oliveira C: Repeated rat-forced swim test: Reducing the number of animals to evaluate gradual effects of antidepressants. J Neurosci Meth 195: 200-205, 2011.
 
13) Moya PR, Fox MA, Jensen CL, Laporte JL, French HT et al.: (2011)Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. BMC Pharmacol 11: 3, 2011.
PubMed
14) Pare WP, Clavin GB: Animal models of stress in pharmacology. Meth Behave Pharmaco 110: 413-441, 1993.
 
15) Pariante CM, Miller AH: Glucocorticoid receptorin major depression: relevance to pathophysiologyand treatment. Biol Psychiatry 49: 391-404, 2001.
 
16) Pei L, Li S, Wang M, Diwan M, Anisman H et al.: Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med 16: 1393-1395, 2010.
PubMed
17) Porsolt RD, Le Pichon M, Jalfre M: Depression a new model sensitive to antidepressanttreatments. Nature 266: 730-732, 1977.
PubMed
18) Seeman P: Brain dopamine receptors. Pharmacol Rev 32: 229-313, 1980.
PubMed
19) Seeman P, Van Tol HH: Dopamine receptor pharmacology. Trends Pharmacol Sci 15: 264-270, 1994.
PubMed
20) Sokoloff P, Diaz J, Levesque D, Pilon C, Dimitriadou V et al.: Novel dopamine receptor subtypes as targets for antipsychotic drugs. Ann NY Acad Sci 757: 278-292, 1995.
PubMed
21) Takeuchi T, Hayashida K, Inagaki H, Kuwahara M, Tsubone H et al.: Opioid mediated suppressive effect of milk-derived lactoferrin on distress induced by maternal separation in rat pups. Brain Res 979: 216-224, 2003.
PubMed
22) Weisstaub NV, Zhou M, Lira A, Lambe E, Gonzalez-Maeso J et al.: Cortical 5-HT2A receptor signalingmodulates anxiety-like behaviors in mice. Science 313: 536-540, 2006.
PubMed
23) Yoshioka M, Matsumoto M, Togashi H, Saito H: Effects of conditioned fear stress on 5-HT release in the rat prefrontal cortex. Pharmacol Biochem Behav 51: 515-519, 1995.
PubMed

書評

最近チェックした商品履歴

Loading...